1 Min Read
Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc
* U.S. FDA approves Auryxia® (ferric citrate) tablets as a treatment for people with iron deficiency anemia and chronic kidney disease, not on dialysis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.